IQVIA CEO to Address Leerink 2026 Conference
RESEARCH TRIANGLE PARK, N.C., March 2, 2026 IQVIA Holdings Inc. (NYSE: IQV) announced that Chairman and Chief Executive Officer...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody NSCLC Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
RESEARCH TRIANGLE PARK, N.C., March 2, 2026 IQVIA Holdings Inc. (NYSE: IQV) announced that Chairman and Chief Executive Officer...
CAMBRIDGE, Mass. | January 8, 2026 — Diagonal Therapeutics, a biotechnology company developing disease-modifying clustering antibody therapies, announced the...
SAN DIEGO | January 8, 2026 — Just – Evotec Biologics, a collaboration between Evotec SE and Just –...
Laupheim and Martinsried, Germany, December 2, 2025 — Rentschler Biopharma, a global contract development and manufacturing organization, and Coriolis...
